Home > Investor > Looking ahead

Looking ahead

Becoming a strong regional player and the first partnering choice

New products

Expanding the product portfolio will strenghten the growth potential.

There is a pharmaceutical development of 11 new medicinal products/projects.
Organic growth

Grow organically in selected new markets to become a strong regional player with stable, geographically diversified revenues by: 

  • Selective entry into new markets with high growth potential
  • Registering and marketing the Company’s branded pharmaceutical products in other EU countries 
  • Continuing to selectively assess acquisition and strategic partnership opportunities
  • Potential for growth on more than 20 markets having less than 1% current share in sales revenues.
    Market position

    Maintain the Company’s position as a leading Bulgarian pharmaceutical manufacturer with high quality affordable products and improve existing products.

    Follow market needs

    5 Marketing Authorization was obtained for a new medicinal product - Solifenax 5 mg film-coated tablet (Bulgaria) ), Ambrolitin 30 mg/5 ml syrop (Bulgaria, Latvia, Estonia), Ketoprofen 100 mg/ 2 ml solution for injection (Bulgaria), Sofazolon 40mg powder and solvent for solution for injection (Bulgaria), Dexketoprofen 50mg/2ml solution for injection (Latvia, Lithuania, Estonia). 

    Intra group integration

    Further consolidate and integrate the Group to optimize its cost structure, control entirely the production chain and benefit from potential synergies.